Next Article in Journal
RETRACTED: Jakfar et al. A Polysaccharide Isolated from the Herb Bletilla striata Combined with Methylcellulose to Form a Hydrogel via Self-Assembly as a Wound Dressing. Int. J. Mol. Sci. 2022, 23, 12019
Previous Article in Journal
Special Issue “Regulation by Non-Coding RNAs 2025”
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 26
Issue 22
10.3390/ijms262210884
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Exploring the Mechanism of Action of Chicoric Acid Against Influenza Virus Infection Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation

by
Weijun Guo
,
Fuhao Ye
,
Zengyao Hou
and
Quanhai Pang
*
College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong 030801, China
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2025, 26(22), 10884; https://doi.org/10.3390/ijms262210884
Submission received: 26 September 2025 / Revised: 2 November 2025 / Accepted: 6 November 2025 / Published: 10 November 2025
(This article belongs to the Section Molecular Pharmacology)
Browse Figures
Versions Notes

Abstract

This study theoretically explores the mechanism of action of Chicoric acid against influenza virus based on network pharmacology, molecular docking, and molecular dynamics simulation techniques, aiming to provide insights for the development of new veterinary drugs for influenza. Potential targets for influenza virus action were identified using the PharmMapper (i.e. Version 2017) server and disease databases including GeneCards and OMIM. The STRING online analysis platform and Cytoscape 3.9.1 software were employed to construct a protein–protein interaction (PPI) network of the target proteins, followed by topological analysis to screen for key targets. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed on the intersecting targets using the DAVID database. A “drug–target–pathway” network diagram was constructed using Cytoscape 3.9.1 software. Molecular docking was carried out with AutoDock 1.5.6 and PyMOL 2.5 software to identify dominant binding targets, followed by molecular dynamics simulation analysis. The results of network analysis showed that there were 31 potential targets of Chicoric acid; the protein interaction network suggested that UBC, UBA52, RPS27A, HCK, and CDKN1B may be the core targets of Chicoric acid; 55 cell biological processes were obtained by GO enrichment analysis, and 15 related signaling pathways were obtained by KEGG pathway enrichment analysis; molecular docking showed that UBC and UBA52 had a good affinity to Chicoric acid and may be the dominant target of Chicoric acid exerting its effect. Chicoric acid may play a role in antiviral activity by acting on the dominant protein of UBC and UBA52, thus achieving an anti-influenza virus effect.

1. Introduction

As a representative pathogen of the Orthomyxoviridae family, the influenza virus exhibits broad host tropism and is capable of causing seasonal epidemics as well as periodic pandemics in both humans and animals [1]. Owing to its considerable zoonotic potential, this virus remains a persistent and serious threat to global public health [2]. Influenza A virus, in particular, presents substantial challenges for disease control, which are largely attributable to its high mutation rate and propensity to develop drug resistance. The continual emergence of resistant viral strains, coupled with the limited repertoire of antiviral drug targets, underscores the urgent need to develop novel and efficient antiviral agents with multi-target mechanisms of action. Given their multi-target activity and favorable toxicity profiles, natural products have thus emerged as a valuable source for identifying antiviral lead compounds in drug discovery.
Chicoric acid, a derivative of caffeic acid, is widely present in various medicinal plants such as Echinacea, chicory, dandelion, Clematis, and coneflower [3,4,5,6,7]. It exhibits a range of pharmacological properties, including antioxidant, free radical-scavenging [8,9], anti-inflammatory, antiviral, antibacterial, and immunomodulatory activities [10,11]. In recent years, its antiviral potential has garnered increasing attention due to its intrinsic capacity to target multiple key viral proteases and enzymes essential for viral replication—such as integrase and polymerase. For instance, in human immunodeficiency virus (HIV) studies, Chicoric acid has been demonstrated to effectively inhibit HIV integrase activity via hydrogen bonding and hydrophobic interactions, thereby preventing the integration of viral DNA into the host genome [12,13]. In severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) research, both molecular docking and in vitro experiments have confirmed that Chicoric acid binds with high affinity to the active sites of the main protease (Mpro/3CLpro) and papain-like protease (PLpro), thereby disrupting viral polyprotein processing and replication [14,15,16]. Furthermore, studies on dengue virus and hepatitis C virus (HCV) have indicated that Chicoric acid also exerts inhibitory effects on viral proteases such as NS2B-NS3 and NS3/4A [17,18,19]. Influenza virus replication similarly relies on key proteins including RNA polymerase subunits (PA, PB1, PB2) and neuraminidase (NA), suggesting that Chicoric acid may interfere with the influenza virus life cycle through analogous mechanisms.
Given the multifaceted bioactivities and therapeutic potential of Chicoric acid, along with the persistent need for effective influenza treatments, it is of significant importance to explore its anti-influenza mechanisms and application prospects. However, the precise molecular mechanisms underlying its anti-influenza activity remain incompletely elucidated. Therefore, this study aims to employ network pharmacology to predict potential targets and signaling pathways involved in the anti-influenza action of Chicoric acid. Molecular docking will be utilized to investigate the binding modes between Chicoric acid and key influenza-related target proteins, and molecular dynamics simulations will be applied to evaluate the stability of these interactions. This integrated approach seeks to clarify the anti-influenza mechanism of Chicoric acid at the molecular level and provide a theoretical foundation for the development of novel anti-influenza therapeutics.

2. Results

2.1. Screening of Targets for Chicoric Acid Against Influenza

A total of 287 potential targets of Chicoric acid were collected from the PharmMapper database, while 3671 influenza virus targets were obtained by integrating data from the GeneCards and OMIM databases. An intersection analysis of potential targets of Chicoric acid and influenza virus was conducted, identifying 31 common candidate targets (Table 1).

2.2. Venn Diagram of Chicoric Acid and Influenza Intersection Targets

This study used the proportional Venn diagram function of the bio-online mapping platform to comparatively analyze the targets of influenza disease and the targets of Chicoric acid, thereby identifying the anti-influenza targets of Chicoric acid (Figure 1).

2.3. Construction of Protein–Protein Interaction Networks

The 31 screened potential anti-influenza targets of Chicoric acid were input into the STRING database with the species restricted to Homo sapiens, resulting in a protein–protein interaction (PPI) network (Figure 2). The network consisted of 31 nodes and 50 edges, with an expected number of edges of 41. The average node degree was 3.23, and the average local clustering coefficient was 0.464. The PPI enrichment p-value was 0.0831. The results were saved as a TSV file. The file was imported into Cytoscape 3.9.1 software, and a bar chart was generated based on the degree values (Figure 3). As shown in the figure, the top five targets were UBA52, RPS27A, UBC, UBB, and CDKN1B. Using the CentiScaPe 2.2 app within the software, a hubs network was constructed with node degree (degree = 4.947), betweenness centrality (betweenness = 22.526), and closeness centrality (closeness = 0.026) as screening criteria to identify core targets. The results are shown in Figure 4. The analysis revealed that the core targets of Chicoric acid against influenza are UBA52, UBC, HCK, CDKN1B, and RPS27A.

2.4. GO/KEGG Analysis Results

The 31 screened targets of Chicoric acid against influenza virus were input into the DAVID database with the species limited to Homo sapiens for GO functional analysis. A total of 55 enrichment results were obtained, including 24 biological processes, 25 cellular components, and 6 molecular functions. Among them, the biological processes involved include the Notch signaling pathway, modification-dependent protein catabolic process, response to exogenous stimuli, positive regulation of cell proliferation, response to L-glutamate, and positive regulation of osteoblast proliferation. The molecular functions involved include protein binding, ubiquitin protein ligase binding, protein tagging, and serine-type endopeptidase activity. Cellular components involved include the cytoplasm, nucleus, extracellular exosome, plasma membrane, vesicle, endoplasmic reticulum membrane, and mitochondrial outer membrane. The top 10 processes ranked by p-value for biological processes, cellular components, and molecular functions in the GO functional analysis were plotted as a bar graph, with the results shown in Figure 5. KEGG pathway analysis yielded a total of 15 pathways. Bubble plots were generated for KEGG pathways with p < 0.05 using R packages from Bioconductor (Figure 6). The anti-influenza virus mechanisms of Chicoric acid primarily involve pathways such as autophagy, Kaposi’s sarcoma-associated herpesvirus infection, pathways of neurodegenerative diseases, shigellosis, and ubiquitin-mediated proteolysis.

2.5. Construction of the Chicoric Acid-Target-Pathway Network

The data obtained from DAVID pathway annotation was used to construct a Chicoric acid-target-pathway network model using Cytoscape 3.9.1 software, as shown in Figure 7. The Network Analyzer results indicated that the network consisted of 47 nodes and 100 edges, with a network density of 0.093, a network diameter of 4, and a network radius of 2. The network centralization was 0.607, network heterogeneity was 1.109, the characteristic path length was 2.331, and the average network degree was 4.255.

2.6. Molecular Docking Validation of Chicoric Acid

The five screened core targets (UBA52, UBC, RPS27A, HCK, and CDKN1B) were selected and subjected to molecular docking with Chicoric acid using AutoDock Tools 1.5.6 software (Table 2). It is generally accepted that a ligand and receptor can spontaneously bind when their binding energy is <0 kJ/mol, and when the binding energy is ≤−20 kJ/mol, they exhibit strong affinity. Although the binding energies of Chicoric acid with all five core targets were <0 kJ/mol, proteins UBC, HCK, and UBA52 demonstrated strong affinity with Chicoric acid, suggesting the potential formation of stable complexes. Thus, proteins UBC, HCK, and UBA52 may represent the dominant binding targets for Chicoric acid. Molecular docking diagrams revealed hydrogen bond interactions between Chicoric acid and all five target proteins. The theoretical binding modes are illustrated in Figure 8.

2.7. Molecular Dynamics Simulation Results

The top three complexes with the highest absolute binding energies with Chicoric acid (UBC, HCK, and UBA52) were selected for molecular dynamics simulation to analyze the stability of the binding between Chicoric acid and the protein targets, as well as the hydrogen bond interactions and binding interactions.

2.7.1. Stability Analysis

RMSD Analysis
RMSD (root mean square deviation) is a commonly used metric to quantify the differences between two structures. It is calculated by comparing the spatial coordinates of corresponding atoms in two molecules, reflecting the conformational similarity between them. It is used to track changes in molecular structure relative to the initial configuration during simulation and to observe whether the magnitude of change stabilizes over time. A lower RMSD value indicates closer structural similarity. As shown in Figure 9A–C, the RMSD values of proteins UBC, HCK, and UBA52 remained largely stable throughout the simulation. Similarly, the RMSD values of the complexes formed with Chicoric acid also remained stable during the simulation, indicating that the structures of the complexes remained generally stable.
Rg Analysis
The radius of gyration (Rg) represents the root mean square distance of all atoms in a molecule relative to its center of mass, reflecting the spatial distribution range of atoms and serving as a key parameter to evaluate the structural compactness of protein–ligand complexes. A smaller Rg value indicates a more compact molecular structure, while a larger Rg suggests a looser, potentially disordered conformation. As shown in Figure 10A–C, the Rg values of the complexes formed between proteins UBC, HCK, and UBA52 and Chicoric acid gradually stabilized during the simulation, indicating that the structures of the complexes attained increasing stability.
RMSF Analysis
Root mean square fluctuation (RMSF) quantifies the flexibility of amino acid residues in a protein by measuring the fluctuation of each atom or residue throughout the molecular dynamics trajectory. It reflects the displacement amplitude of each atom or residue relative to its average position, aiding in the identification of flexible and rigid regions within the molecule. As shown in Figure 11A–C, the simulation results are consistent with the crystal structure.
Centroid Evolution Analysis
To analyze the state of the small molecule on the protein surface and identify its initial docking site, the distance between the centroid of residues at the initial docking site and the centroid of the small molecule was calculated. Additionally, the distance between the small molecule and the protein centroid was analyzed to evaluate the binding status. As shown in Figure 12A–C, the distances between Chicoric acid and the centroids of the three proteins (UBC, HCK, UBA52), as well as the distance between Chicoric acid and its initial binding site, gradually stabilized. This indicates that the small molecule stably binds to the initial binding site of the proteins, and the binding between the small molecule and the proteins progressively stabilizes.
Buried SASA Analysis
Buried solvent-accessible surface area (Buried SASA) is a metric used to evaluate the regions within a molecule or molecular complex that are buried internally and inaccessible to solvent. A larger Buried SASA value indicates stronger intermolecular interactions and a larger contact area. As shown in Figure 13A–C, the Buried SASA values gradually stabilized, suggesting that the contact area between Chicoric acid and the three proteins (UBC, HCK, UBA52) became increasingly consistent, and the binding between them progressively stabilized.
Superposition of Binding Conformations
The simulation trajectories were processed to superimpose the simulated conformations, with the results shown in Figure 14A–C. The high degree of conformational overlap for Chicoric acid indicates that the small molecule consistently remained bound to the initial binding site throughout the simulation.

2.7.2. Analysis of Hydrogen Bond Interactions Between the Small Molecule and Proteins

Evolution of Hydrogen Bond Numbers
Hydrogen bonding is a critical interaction force in protein–ligand binding, related to electrostatic interactions and reflecting their strength. The number of hydrogen bonds between Chicoric acid and protein UBC fluctuated primarily between 0 and 1 (Figure 15A), while with protein HCK, it fluctuated between 2 and 5 (Figure 15B). In contrast, the number of hydrogen bonds with protein UBA52 remained between 1 and 5 (Figure 15C).
Hydrogen Bond Occupancy (Frequency) Analysis
Hydrogen bond frequency analysis is a common method for studying the formation and persistence of intermolecular or intramolecular hydrogen bonds. It is used to determine the formation frequency, duration, and distribution of hydrogen bonds during the simulation. This analysis can identify high-frequency hydrogen bonds formed between the ligand and specific amino acid residues in the binding site, suggesting their critical role in the binding process. As shown in the figures, the left side displays the acceptor, donor, and occupancy of hydrogen bond pairs, while the right side shows the corresponding hydrogen bond formation frequency, with line density indicating the frequency level. According to Figure 16A–C, the hydrogen bonds formed between proteins UBC and HCK with Chicoric acid exhibit relatively low stability. In contrast, protein UBA52 and Chicoric acid demonstrate hydrogen bond pairs with higher stability, such as Ligand:317PRO, with an occurrence frequency of 59.9%, indicating strong stability.

2.7.3. Analysis of Interactions Between the Small Molecule and Proteins

Analysis of Electrostatic and van der Waals Interactions
Without considering solvation effects, the van der Waals (VDW) and electrostatic (ELE) interactions between the small molecule and the protein in the complex were calculated to analyze changes in binding forces during the simulation. VDW represents van der Waals and hydrophobic interactions, while ELE denotes electrostatic interactions. The sum of VDW and ELE (binding) reflects the binding energy between the small molecule and the protein in the absence of solvation effects. As shown in Figure 17A–C, both VDW and ELE interactions in the three protein complexes (UBC, HCK, and UBA52) gradually stabilized during the simulation, indicating that the binding between the small molecule and the proteins became increasingly stable.
Binding Energy Analysis
Considering solvation energy and integrating RMSD, Rg, Distance, Buried SASA, and interaction energy, the stable-state trajectories of the complexes were selected. The MM-PBSA (Molecular Mechanics-Poisson Boltzmann Surface Area) method was employed to calculate the relevant energy terms of binding energy, as shown in Table 3a–c.
Among them, ΔEele represents the electrostatic interaction between the small molecule and the protein, ΔEvdw denotes the van der Waals interaction, ΔEpol indicates the polar solvation energy (reflecting electrostatic potential energy), and ΔEnonpol represents the non-polar solvation energy (reflecting hydrophobic interactions). ΔEMMPBSA is the sum of ΔEele, ΔEvdw, ΔEpol, and ΔEnonpol. The Gibbs binding energy ΔGbind is the sum of ΔEMMPBSA and −TΔS. (Note: Due to the significant computational error associated with -TΔS, this term is often excluded in binding energy comparisons, and ΔEMMPBSA is directly used as the binding energy. Additionally, the calculation of polar solvation energy ΔEpol also carries substantial uncertainty; thus, focus may be placed on other energy terms such as ΔEele, ΔEvdw, and ΔEnonpol.)
Based on the analysis of Table 3a, in the UBC protein complex, the van der Waals interaction energy (ΔEvdw) is higher than the electrostatic interaction energy (ΔEele), and both are higher than the hydrophobic interaction energy (ΔEnonpol). Therefore, in the composition of the binding energy, van der Waals interactions play a dominant role, electrostatic interactions play a secondary role, and hydrophobic interactions serve a supplementary role. The ΔEMMPBSA between the small molecule and the protein is −45.697 ± 1.277 kJ/mol, indicating high binding energy and strong affinity between them.
Based on the analysis of Table 3b, in the HCK protein complex, the van der Waals interaction energy (ΔEvdw) is higher than the electrostatic interaction energy (ΔEele), with van der Waals and electrostatic interactions being comparable in magnitude. Thus, in the composition of the binding energy, van der Waals interactions and electrostatic interactions play dominant roles, while hydrophobic interactions play a secondary role. The ΔEMMPBSA between the small molecule and the protein is −11.031 ± 5.742 kJ/mol, indicating relatively high binding energy and affinity between them.
Based on the analysis of Table 3c, in the UBA52 protein complex, the van der Waals interaction energy (ΔEvdw) is higher than the hydrophobic interaction energy (ΔEnonpol), while the electrostatic interaction energy (ΔEele) is comparable to the hydrophobic interaction energy. Therefore, in the composition of the binding energy, van der Waals interactions play a dominant role, while hydrophobic interactions and electrostatic interactions play secondary roles. The ΔEMMPBSA between the small molecule and the protein is −139.443 ± 2.563 kJ/mol, indicating high binding energy and strong affinity between them.
Residue Contribution Analysis
The binding energy ΔEMMPBSA was decomposed to determine the contribution of each amino acid to the overall binding energy, thereby identifying critical residues in the protein. For the UBC protein, key amino acids contributing significantly to the binding energy include PHE-313 and GLN-471, as shown in Figure 18A. For the HCK protein, critical residues such as VAL-130 and THR-33 are highlighted in Figure 18B.
Similarly, for the UBA52 protein, key amino acids including PRO-317 and ARG-316 are illustrated in Figure 18C.
Structural Analysis
The conformation at the stable stage of the simulation was selected to analyze its structure and interactions. As shown in Figure 19A, amino acids PRO-122, MET-213, ARG-288, and GLN-471 in the UBC protein formed hydrogen bonds with the small molecule. MET-213, PHE-119, TYR-187, ALA-121, and PHE-313 engaged in hydrophobic interactions with the small molecule, including Pi–Sulfur, Pi-Pi Stacked, Pi-Pi T-shaped, and Pi–Alkyl interactions. Amino acids such as GLN-123 and ARG-473 participated in van der Waals interactions with the small molecule.
As illustrated in Figure 19B, the small molecule interacts with the HCK protein through multiple forces. It forms conventional hydrogen bonds with ASP-131, LEU-34, GLN-134, and THR-128. Additionally, a Pi-alkyl interaction is observed with VAL-130, while other residues, including ASP-36 and ILE-126, participate through van der Waals contacts.
As shown in Figure 19C, amino acids PRO-317, LEU-103, and SER-243 in the UBA52 protein formed hydrogen bonds with the small molecule. ARG-316 and PRO-101 engaged in hydrophobic interactions with the small molecule, including Pi-Cation, Amide-Pi Stacked, and Pi-Alkyl interactions. Amino acids such as GLN-99 and ASN-104 participated in van der Waals interactions with the small molecule.

3. Discussion

Currently, the application of network pharmacology technology has achieved promising results in predicting drug targets and studying their mechanisms. Huang Can et al. [20], in their study on the mechanism of action of cepharanthine against SARS-CoV-2, utilized PubChem, the DAVID database, the STRING database, and the molecular docking method to predict key proteins. They identified 40 intersection targets between cepharanthine and COVID-19, with key targets primarily involving Src, AKT1, EGFR, and mTOR, among others. Jin Yaqing et al. [21], in their study on the mechanism of Elsholtzia splendens in treating influenza, utilized databases such as TCMSP, GeneCards, OMIM, DAVID, and STRING to identify nine core proteins including Akt serine/threonine kinase 1 (Akt1), non-receptor tyrosine kinase (SRC), heat shock protein (HSP) 90AA1, epidermal growth factor receptor (EGFR), matrix metalloproteinase 9 (MMP9), prostaglandin–endoperoxide synthase 2 (PTGS2), and mechanistic target of rapamycin (mTOR). These findings suggest that Elsholtzia splendens may exert anti-influenza effects through multiple mechanisms, including direct antiviral activity, immunomodulation, and anti-inflammatory actions. Li Zhi et al. [22], in their study on the mechanism of baicalein against porcine deltacoronavirus (PDCoV) infection, identified common targets of baicalein and PDCoV infection through databases such as PharmMapper, PubChem, STRING, TCMSP, and Swiss Target Prediction. Their findings indicated that baicalein’s anti-PDCoV effects exhibit multi-target and multi-pathway characteristics, potentially acting on core genes including AKT1, HSP90AA1, SRC, EGFR, CASP3, MAPK, and STAT3 to regulate the PI3K-Akt, Ras, and MAPK signaling pathways, apoptosis, viral infection, and other processes.
This study employed the PharmMapper, GeneCards, and OMIM databases to identify 31 common candidate targets shared between Chicoric acid and the influenza virus. Based on 31 candidate targets, a protein–protein interaction (PPI) network was constructed using the STRING and Cytoscape databases, and five core targets—UBA52, UBC, HCK, CDKN1B, and RPS27A—were screened based on their degree, betweenness centrality, and closeness centrality.
Both UBA52 and UBC function as essential precursors for intracellular free ubiquitin and play critical roles in maintaining the integrity and functionality of the ubiquitin–proteasome system. Deficiency in UBA52 has been associated with cell cycle arrest, impaired DNA repair capacity, and diminished protein synthesis [23,24]. Notably, Qiao W et al. [25] reported that the host protein UBA52 interacts with H5N1 avian influenza viral proteins PA, PAN155, and PAN182, thereby modulating viral replication. UBC is recognized as a canonical heat shock response protein, whose transcriptional upregulation under proteotoxic stress—including heat shock or proteasome inhibition—is primarily mediated by the binding of heat shock factor 1 (HSF1) to the heat shock element (HSE) located in its promoter region [26,27]. Supporting this mechanism, Bianchi M et al. [28] demonstrated that Nrf2 knockdown in HeLa cells does not alter stress-induced UBC expression, whereas arsenite-induced stress enhances UBC expression in an HSF1-dependent but Nrf2-independent manner. This study proposes that Chicoric acid, owing to its structural resemblance to ubiquitin or ubiquitin-binding domains (e.g., UBA, UBD), may competitively interact with UBA52 and UBC proteins. Such an interaction could occupy the molecular interfaces required for their association with E3 ubiquitin ligases or substrate proteins, potentially disrupting the stability and functional dynamics of key proteins involved in the influenza virus life cycle. Concurrently, this interference may exacerbate cell cycle arrest resulting from UBA52 dysfunction, thereby indirectly suppressing viral replication, which depends on active host cell cycling.
HCK, a member of the Src family of kinases, is predominantly expressed in myeloid cells and plays a pivotal role in regulating inflammatory responses and cell migration. It modulates key cellular processes through activation of the NLRP3 inflammasome [29], induction of macrophage M2 polarization [30], and regulation of EGFR expression [31]. This study proposes that Chicoric acid may act as a potent inhibitor of HCK kinase activity, potentially through competitive binding to the ATP-binding pocket or interaction with allosteric regulatory sites, thereby disrupting downstream signaling pathways involved in viral propagation and inflammation. Given that HCK substrates are critically involved in cytoskeletal reorganization—mediating viral endocytosis—and in inflammatory signal transduction, including NF-κB pathway activation, HCK inhibition is likely to confer dual antiviral benefits: suppression of viral entry during the early stages of infection and attenuation of excessive host inflammatory responses in later phases. This mechanistic rationale is consistent with the broad-spectrum antiviral activity demonstrated by established Src family kinase inhibitors such as Dasatinib [32,33], offering a plausible explanation for the observed pharmacological effects of Chicoric acid and further supporting the therapeutic potential of targeting Src family kinases in antiviral interventions.
CDKN1B is a key cyclin-dependent kinase inhibitor that negatively regulates cell proliferation by arresting the cell cycle at the G1 phase and participates in the regulation of apoptosis [34,35,36,37,38,39]. Decreased expression of CDKN1B has been linked to poor prognosis in multiple types of tumors [40,41]. We hypothesize that Chicoric acid may directly bind to the CDKN1B protein, stabilizing its conformation and protecting it from degradation via phosphorylation- and ubiquitination-dependent pathways triggered by viral or oncogenic proteins. The resulting accumulation of CDKN1B protein is expected to induce G1 phase cell cycle arrest, thereby preventing viruses from entering the S phase and exploiting replication resources available during this stage. This process ultimately leads to the suppression of viral genome replication and proliferation.
RPS27A is a non-conventional ribosomal protein that serves not only as a component of the ribosome but also as a ubiquitin precursor (UBA80), independently participating in cell cycle regulation, apoptosis, and transcriptional control [42,43,44]. It can induce cell cycle arrest via the Raf/MEK/ERK pathway and stabilize p53 by suppressing MDM2 [45,46]. RPS27A is highly expressed in various cancers and virus-infected liver tissues [47,48,49,50,51]. We propose that Chicoric acid disrupts RPS27A function through two synergistic mechanisms: First, it directly targets RPS27A, impairing its role in ribosome biogenesis or translation initiation, thereby globally reducing host protein synthesis and directly inhibiting rapid viral protein production. Second, Chicoric acid interferes with the maturation of RPS27A into ubiquitin, disturbing the intracellular free ubiquitin equilibrium. This latter effect may act in concert with the inhibitory action of Chicoric acid on UBA52/UBC, amplifying the overall disruption of the ubiquitin–proteasome system. Together, these actions suppress viral proliferation by simultaneously targeting viral protein synthesis and host cell homeostasis.
To further validate the network pharmacology findings, molecular docking and molecular dynamics simulations were employed to evaluate the binding affinity and stability of the complexes between the screened protein targets and Chicoric acid at the molecular level, under both static and dynamic conditions. According to Sun et al. [52], a binding energy below 0 kJ/mol suggests spontaneous binding, while a value lower than −20 kJ/mol indicates stable complex formation. Our molecular docking results demonstrated that all five core proteins bound spontaneously to Chicoric acid, with binding energies below 0 kJ/mol. Among them, UBC and UBA52 exhibited the lowest values.
Molecular dynamics (MD) simulations were performed on the top three protein targets—UBC, HCK, and UBA52—selected based on molecular docking binding energies. The simulation results further validated the feasibility of the docking-based conclusions. In this study, 100 ns MD simulations were conducted to systematically evaluate the binding characteristics and conformational dynamics of Chicoric acid with UBA52, HCK, and UBC. Analysis of the MD trajectories indicated that all three protein–Chicoric acid complexes maintained good structural stability throughout the simulation. Root mean square deviation (RMSD) analysis revealed that the UBC complex reached equilibrium rapidly within 10 ns and remained stable at approximately 0.25 nm. In contrast, UBA52 and HCK underwent brief conformational adjustments before stabilizing at around 0.2–0.4 nm and 0.3 nm, respectively. Notably, the RMSD profiles of Chicoric acid closely matched those of the corresponding protein backbones in all systems, suggesting a stable binding mode without significant displacement or flipping. Local flexibility, assessed by root mean square fluctuation (RMSF), indicated elevated fluctuations in non-binding regions (e.g., residues 50–70, 150–170, and 250–280 in UBA52; 40–60, 120–140, and 170–190 in HCK; 150–170 and 380–400 in UBC). However, residues within the binding pockets exhibited markedly reduced RMSF values, indicating that Chicoric acid binding restricted local structural fluctuations and exerted a stabilizing effect at the binding site. Structural compactness and hydrophobic core stability further supported these observations [53]. The radius of gyration (Rg) values for UBA52, HCK, and UBC stabilized within narrow ranges of 2.15–2.25 nm, 2.04–2.08 nm, and 2.55–2.61 nm, respectively, indicating that ligand binding did not compromise overall structural compactness. Moreover, minimal variation in the solvent-accessible surface area (SASA) suggested tight packing of hydrophobic cores without significant exposure due to structural relaxation. Binding free energy calculations indicated that Chicoric acid affinity followed the order UBA52 > UBC > HCK, with electrostatic interactions (ELE) serving as the primary driving force. The contribution of ELE increased with higher binding affinity. Hydrogen bond analysis and binding distance measurements further highlighted differences in binding stability: UBA52 and UBC complexes maintained 0–1 and 1–5 hydrogen bonds, respectively, with binding distances under 0.3 nm, whereas the HCK system formed 2–5 hydrogen bonds with distances slightly exceeding 0.3 nm. Energy decomposition per residue revealed distinct binding mechanisms across the proteins: in HCK, Chicoric acid interacted mainly with acidic residues such as GLU40 and ASP36; in UBC, polar residues ASP28 and GLU311 dominated; and in UBA52, basic residues ARG316, ARG320, and LYS217 contributed most significantly—suggesting potential salt bridge formation with the carboxyl groups of Chicoric acid, consistent with the highest binding affinity in this system. Hydrophobic residues, including LEU29 (HCK), PHE313 (UBC), and LEU103 (UBA52), also participated in ligand binding across all systems, indicating a general role for hydrophobic effects in stabilizing the binding mode. Analysis reveals that Chicoric acid exhibits a conserved binding mechanism across UBA52, HCK, and UBC, defined by a synergistic pattern of dominant electrostatic interactions, complemented by hydrogen bonding and hydrophobic contributions. Notwithstanding this shared mechanism, pronounced differences are observed in the specific residue involvement and binding conformations.

4. Materials and Methods

4.1. Screening of Chicoric Acid Targets

The 3D structure of Chicoric acid (CAS: 70831-56-0) was obtained from the PubChem database (https://pubchem.ncbi.nlm.nih.gov (accessed on 19 April 2024)) [54] in SDF format and submitted to the PharmMapper (http://www.lilab-ecust.cn/pharmmapper/ (accessed on 19 April 2024)) [55] server for analysis. The submission employed the “Druggable Pharmacophore Models” set, with the parameter for the number of matched targets set to 300, which returned the top 300 potential targets based on fit score. A subsequent query of these target names using the UniProtKB search function in the UniProt database converted all identifications to their official gene symbols (Official Symbols) for consistency.

4.2. Screening of Influenza Targets

Retrieval was performed using the keyword “influenza virus” in the GeneCards database (https://www.genecards.org/ (accessed on 21 April 2024)) [56] and the OMIM database (https://omim.org/ (accessed on 1 May 2024)) [57,58] to acquire and screen target data related to influenza. The targets screened from both disease databases were processed by removing duplicate entries, resulting in a set of targets associated with influenza virus.

4.3. Visual Analysis of Chicoric Acid Against Influenza Virus

A Venn diagram was plotted using the online bioinformatics platform (http://www.bioinformatics.com.cn/ (accessed on 10 May 2024)) [59] to visualize the anti-influenza virus effects of Chicoric acid.

4.4. Construction and Analysis of the Protein–Protein Interaction Network

The protein–protein interaction (PPI) network for the potential targets of Chicoric acid against influenza was constructed using the STRING database (https://string-db.org/ (accessed on 11 May 2024)) [60], with the organism limited to Homo sapiens and an interaction score threshold set to medium confidence (0.400). The resulting TSV file from STRING was imported into Cytoscape 3.9.1 [61] for network visualization and analysis. Subsequently, the CentiScaPe 2.2 application analyzed this network to screen for the core targets based on topological algorithms.

4.5. GO Functional Enrichment Analysis and KEGG Pathway Analysis

Access the DAVID database (https://david.ncifcrf.gov/) [62], import the potential targets of Chicoric acid against influenza, and select the species “Homo sapiens”. Set the “Select Identifier” to “OFFICIAL_GENE_SYMBOL” and the “List Type” to “Gene List”. Perform GO analysis and KEGG [63] pathway analysis on the targets of Chicoric acid against influenza, and export the results as a TXT file. Screening was conducted according to p < 0.05. Arranged in ascending order, bar charts were drawn for the top 10 biological processes in terms of the number of targets in the three branches of GO, namely biological processes, molecular functions, and cellular components. Use the R package in Bioconductor to draw bubble charts for the top 20 KEGG pathways in terms of the number of targets.

4.6. Construction of the Drug–Target–Pathway Network

Access Cytoscape 3.9.1 software, import the targets and pathway information related to Chicoric acid’s anti-influenza activity, and construct a “drug–target–pathway” network diagram.

4.7. Molecular Docking Validation of Chicoric Acid with Targets

Access the PubChem database to download the structure of the ligand Chicoric acid and save it in SDF format. Use Open Babel to convert it to MOL2 format. Open the small ligand molecule with AutoDock Tools 1.5.6 [64,65]; then, add hydrogen atoms, assign charges, detect the root of the ligand, perform rotatable bond search and definition, and save the file in PDBQT format. Access the RCSB Protein Data Bank to download the 3D structure of the core target protein. In AutoDock Tools 1.5.6, perform molecular docking between Chicoric acid and the important target proteins. After steps such as dehydration and adding hydrogen, use the Auto Grid and Auto Dock modules to perform the docking and obtain the binding affinity. Use Open Babel 2.4.1 software to convert the molecular docking results from the aforementioned PDBQT format files into PDB files. Select the conformation with the lowest docking binding energy for binding mode analysis, and use PyMOL to visualize the molecular docking results, plot intermolecular hydrogen bonds, and add labels.

4.8. Molecular Dynamics Simulation

To further investigate the stability of the binding between the small ligand molecule and the large protein molecule, molecular dynamics simulations were performed on the protein receptors with high binding energy to the ligand molecule using the software. The molecular dynamics (MD) simulations were conducted using the Gromacs 2022 [66,67] program. The GAFF force field was applied to the small molecule, while the AMBER14SB force field and TIP3P water model were used for the protein. The files of the protein and the small-molecule ligand were merged to construct the simulation system for the complex. The simulations were performed under constant temperature and pressure with periodic boundary conditions. During the MD simulation, all involved hydrogen bonds were constrained using the LINCS algorithm, with an integration time step of 2 fs. Electrostatic interactions were calculated using the Particle-mesh Ewald (PME) method, with a cutoff set to 1.2 nm. The non-bonded interaction cutoff was set to 10 Å and updated every 10 steps. The V-rescale temperature coupling method was employed to maintain the simulation temperature at 298 K, while the Berendsen method was used to control the pressure at 1 bar. At 298 K, 100 ps of NVT and NPT equilibrium simulations were performed, followed by a 100 ns MD simulation of the complex system, with conformations saved every 10 ps. After the simulation, VMD and PyMOL were used to analyze the simulation trajectory, and the g_mmpbsa program was applied to calculate the MMPBSA binding free energy between the protein and the small-molecule ligand.

5. Conclusions

In summary, this study systematically elucidated the molecular mechanisms through which Chicoric acid exerts anti-influenza effects via multi-target and multi-pathway synergy, employing an integrated computational strategy that combined network pharmacology, molecular docking, and molecular dynamics simulations. The results demonstrate that Chicoric acid exhibits stable binding affinity with key targets such as UBC and UBA52. The structural basis of these interactions was characterized at the atomic level, providing a theoretical foundation for developing Chicoric acid as a novel multi-target anti-influenza agent.
However, it should be noted that although the integrated computational approach adopted in this study enabled a shift from a single-target to a network-level perspective, enhanced screening efficiency from broad to focused analysis, and offered deeper mechanistic insights by transitioning from static binding evaluation to dynamic simulation, certain limitations remain. For instance, network pharmacology analyses are constrained by the completeness and accuracy of underlying databases, which may introduce systematic bias. Computational simulations, as simplified models of complex biological systems, cannot fully recapitulate actual binding conformations or dynamic processes in vivo. Most importantly, in the absence of experimental validation, the findings of this study remain hypothetical, and their biological relevance and translational potential require further confirmation.
To address these limitations, future research should focus on integrating computational predictions with rigorously designed experimental studies. Key targets and pathways should be systematically verified using in vitro antiviral assays, cellular molecular biology techniques, and animal models. Further efforts should aim to clarify the specific sites of action of Chicoric acid within multiple pathways and to quantify the relative contributions of individual targets to the observed synergistic effects. Moreover, incorporating multi-omics data to develop predictive models that more accurately reflect real biological systems will improve the reliability of computational strategies and facilitate the translation of Chicoric acid into preclinical research.

Author Contributions

W.G.: Investigation, project administration, visualization, and writing—original draft and editing. F.Y.: Methodology, project administration, and data curation. Z.H.: Formal analysis. Q.P.: Conceptualization, resources, review, supervision, review—editing, and funding acquisition. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by National Natural Science Foundation (Grants NO.32273089); National Natural Science Foundation (Grants NO.31872532); National Natural Science Foundation (Grants NO.31272628); National Natural Science Foundation (Grants NO.30972223).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within the article.

Acknowledgments

The author sincerely thanks all public databases and open-source software that have supported this research, including but not limited to Genecards, pharmmapper, OMIM, STRING, SwissTargetPrediction, DAVID, and Cytoscape, as well as the development and maintenance teams of AutoDock and GROMACS. Their work has provided an essential foundation for the smooth progress of this research.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Margine, I.; Krammer, F. Animal models for influenza viruses: Implications for universal vaccine development. Pathogens 2014, 3, 845–874. [Google Scholar] [CrossRef]
  2. Glezen, W.P. Emerging infections: Pandemic influenza. Epidemiol. Rev. 1996, 18, 64–76. [Google Scholar] [CrossRef] [PubMed]
  3. Wu, Q.; Yuan, Q.; Chen, Y. Study on extraction and purification process of cichoric acid in Echinacea purpurea. Chin. Tradit. Herb. Drugs 2004, 9, 995–997. [Google Scholar]
  4. Hua, C.; Li, J.; Zhou, F.; Zhou, Q.; Zhang, B.; Wang, R.; Zhao, M. Process Optimization for Cichoric Acid Extraction from Cichorium lntybus L. Shoots. Food Sci. 2011, 32, 126–129. [Google Scholar]
  5. Huang, Q.; Feng, H.; Li, M.; Qiu, F.; Jiang, Z. Determination of Cichoric Acid in Dandelion Extract from Different Areas. Mod. Food 2021, 14, 177−178+186. [Google Scholar]
  6. Zhang, X.; Shi, B.; Li, Y.; Li, Y.; Ye, W. Chemical constituents in aerial parts of Pulsatilla chinensis. Chin. Tradit. Herb. Drugs 2008, 5, 651–653. [Google Scholar]
  7. Wang, H.; Liu, W.; Lu, X.; Chen, S.; Ai, T. Determination of Cichoric Acid in Echinacea purpuea. China J. Chin. Mater. Med. 2002, 27, 418–420. [Google Scholar]
  8. Xiao, H.; Yang, S.; Wang, X.; Wang, J.; Song, Y. Effect of Chicoric Acid on Oxidative Protein Damage. Food Sci. 2018, 39, 119–124. [Google Scholar]
  9. Meng, C.; Fu, H.; Zhou, L.; lei, Y.; Wang, Y. Studies on the Antioxidative Activity and Inhibitory Kinetics on Tyrosinase-catalyzing Reaction of Cichoric Acid. J. Chin. Inst. Food Sci. Technol. 2017, 17, 53–59. [Google Scholar]
  10. Wang, Y.; Gao, S.; Li, L.; Zhang, L.; Sun, Y.; Bo, F. Research advances on bioactivity and pharmacological effects of chicoric acid. Chin. J. New Drug 2020, 29, 1729–1733. [Google Scholar]
  11. Wu, C.; Li, J.; Cong, X.; Gao, Y.; Yu, F.; Lv, Y.; Yang, M.; Li, J.; Feng, S.; Li, F. Antiviral and Antibacterial Effect of Chicoric Acid: A Review. Chin. J. Exp. Tradit. Med. Formulae 2022, 28, 220–228. [Google Scholar]
  12. Healy, E.F.; Sanders, J.; King, P.J.; Robinson, W.E., Jr. A docking study of L-chicoric acid with HIV-1 integrase. J. Mol. Graph. Model. 2009, 27, 584–589. [Google Scholar] [CrossRef]
  13. Nobela, O.; Renslow, R.S.; Thomas, D.G.; Colby, S.M.; Sitha, S.; Njobeh, P.B.; du Preez, L.; Tugizimana, F.; Madala, N.E. Efficient discrimination of natural stereoisomers of chicoric acid, an HIV-1 integrase inhibitor. J. Photochem. Photobiol. B Biol. 2018, 189, 258–266. [Google Scholar] [CrossRef]
  14. Verma, D.; Mitra, D.; Paul, M.; Chaudhary, P.; Kamboj, A.; Thatoi, H.; Janmeda, P.; Jain, D.; Panneerselvam, P.; Shrivastav, R.; et al. Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PLpro and Mpro/3CLpro: Molecular docking and simulation studies of three pertinent medicinal plant natural components. Curr. Res. Pharmacol. Drug Discov. 2021, 2, 100038. [Google Scholar] [CrossRef] [PubMed]
  15. Karpiński, T.M.; Kwaśniewski, M.; Ożarowski, M. In silico studies of selected xanthophylls as potential candidates against SARS-CoV-2 targeting main protease (Mpro) and papain-like protease (PLpro). Herba Pol. 2021, 67, 1–8. [Google Scholar] [CrossRef]
  16. Abd El-Aziz, N.M.; Khalifa, I.; Darwish, A.M.; Badr, A.N.; Aljumayi, H.; Hafez, E.-S.; Shehata, M.G. Docking analysis of some bioactive compounds from traditional plants against SARS-CoV-2 target proteins. Molecules 2022, 27, 2662. [Google Scholar] [CrossRef] [PubMed]
  17. Šilhár, P.; Čapková, K.; Salzameda, N.T.; Barbieri, J.T.; Hixon, M.S.; Janda, K.D. Botulinum neurotoxin A protease: Discovery of natural product exosite inhibitors. J. Am. Chem. Soc. 2010, 132, 2868–2869. [Google Scholar] [CrossRef]
  18. Meeprasert, A.; Rungrotmongkol, T.; Suan Li, M.; Hannongbua, S. In silico screening for potent inhibitors against the NS3/4A protease of hepatitis C virus. Curr. Pharm. Des. 2014, 20, 3465–3477. [Google Scholar] [CrossRef]
  19. Guo, Y.; Hui, C.; Xiong, W.; Zhang, W. Advances in antiviral therapy targeting to hepatitis C virus NS3/4A protease. Chin. J. Clin. Infect. Dis. 2014, 7, 89–93. [Google Scholar]
  20. Huang, C.; Niu, Y.; Nan, Y.; Yuan, L.; Dou, H.L.; Jiang, W.J. Exploring the Mechanism of Cepharanthine in the Treatment of COVID-19 Based on Network Pharmacology and Molecular Docking Technology. J. Ningxia Med. Univ. 2023, 45, 531–540. [Google Scholar]
  21. Jin, Y.; Zu, M.; Hong, Y.; Li, L. Research on the mechanism of anti-influenza effect of Moslae Herba based on network pharmacology. Mil. Med. Sci. 2022, 46, 691–698. [Google Scholar]
  22. Li, Z.; Qian, R.; Wang, Y. Study on mechanism of modified Fuzilizhong decoction in treating bovine diarrhea based on network pharmacology. Heilongjiang Anim. Sci. Vet. Med. 2021, 15, 75−84+153. [Google Scholar]
  23. Xu, X.; Dong, Y.; Liu, M.; Li, Y.; Zhang, Y. Clinical significance of UbA52 level in the urine of patients with type 2 diabetes mellitus and diabetic kidney disease. Nefrología 2021, 41, 548–555. [Google Scholar] [CrossRef] [PubMed]
  24. Kobayashi, M.; Oshima, S.; Maeyashiki, C.; Nibe, Y.; Otsubo, K.; Matsuzawa, Y.; Nemoto, Y.; Nagaishi, T.; Okamoto, R.; Tsuchiya, K.; et al. The ubiquitin hybrid gene UBA52 regulates ubiquitination of ribosome and sustains embryonic development. Sci. Rep. 2016, 6, 36780. [Google Scholar] [CrossRef]
  25. Wang, Q.; Li, Q.; Liu, T.; Chang, G.; Sun, Z.; Gao, Z.; Wang, F.; Zhou, H.; Liu, R.; Zheng, M.; et al. Host interaction analysis of PA-N155 and PA-N182 in chicken cells reveals an essential role of UBA52 for replication of H5N1 avian influenza virus. Front. Microbiol. 2018, 9, 936. [Google Scholar] [CrossRef]
  26. Crinelli, R.; Bianchi, M.; Radici, L.; Carloni, E.; Giacomini, E.; Magnani, M. Molecular dissection of the human ubiquitin C promoter reveals heat shock element architectures with activating and repressive functions. PLoS ONE 2015, 10, e0136882. [Google Scholar] [CrossRef]
  27. Vihervaara, A.; Sergelius, C.; Vasara, J.; Blom, M.A.; Elsing, A.N.; Roos-Mattjus, P.; Sistonen, L. Transcriptional response to stress in the dynamic chromatin environment of cycling and mitotic cells. Proc. Natl. Acad. Sci. USA 2013, 110, E3388–E3397. [Google Scholar] [CrossRef]
  28. Bianchi, M.; Crinelli, R.; Arbore, V.; Magnani, M. Induction of ubiquitin C (UBC) gene transcription is mediated by HSF 1: Role of proteotoxic and oxidative stress. FEBS Open Bio 2018, 8, 1471–1485. [Google Scholar] [CrossRef]
  29. Kong, X. To Study the Mechanism of Hematopoietivvell Kinase (HCK) Regulate NLRP3INFLAMMASOME Activation. Master’s Thesis, LanZhou University, Lanzhou, China, 2017. [Google Scholar]
  30. Luo, S. Construction of Kinases Gene Co-Expression Network in Glioma Andregulation of Tumor-Associated Macrophages by Identifiedimmune-Associated Kinase Gene HCK. Master’s Thesis, China Medical University, Shenyang, China, 2023. [Google Scholar]
  31. Zhang, C.; Qu, X.H. Effects of Hck Gene on Proliferation and Invasion of Lung Adenocarcinoma Cells via EGFR Pathway. China Contin. Med. Educ. 2020, 12, 162–166. [Google Scholar]
  32. Roskoski, R., Jr. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol. Res. 2015, 94, 9–25. [Google Scholar] [CrossRef]
  33. Weisberg, E.; Parent, A.; Yang, P.L.; Sattler, M.; Liu, Q.; Liu, Q.; Wang, J.; Meng, C.; Buhrlage, S.J.; Gray, N.; et al. Repurposing of kinase inhibitors for treatment of COVID-19. Pharm. Res. 2020, 37, 167. [Google Scholar] [CrossRef]
  34. Hershko, D.D.; Shapira, M. Prognostic role of p27Kip1 deregulation in colorectal cancer. Cancer 2006, 107, 668–675. [Google Scholar] [CrossRef]
  35. He, W.; Wang, X.; Chen, L.; Guan, X. A crosstalk imbalance between p27kip1 and its interacting molecules enhances breast carcinogenesis. Cancer Biother. Radiopharm. 2012, 27, 399–402. [Google Scholar] [CrossRef] [PubMed]
  36. Wu, J.; Wang, R.; Kan, X.; Zhang, J.; Sun, W.; Goltzman, D.; Miao, D. A Sonic Hedgehog-Gli-Bmi1 signaling pathway plays a critical role in p27 deficiency induced bone anabolism. Int. J. Biol. Sci. 2022, 18, 956–969. [Google Scholar] [CrossRef] [PubMed]
  37. Park, B.M.; Roh, J.-i.; Lee, J.; Lee, H.-W. Generation of knockout mouse models of cyclin-dependent kinase inhibitors by engineered nuclease-mediated genome editing. Lab. Anim. Res. 2018, 34, 264–269. [Google Scholar] [CrossRef] [PubMed]
  38. Wurz, K.; Garcia, R.L.; Goff, B.A.; Mitchell, P.S.; Lee, J.H.; Tewari, M.; Swisher, E.M. MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival. Genes Chromosomes Cancer 2010, 49, 577–584. [Google Scholar] [CrossRef]
  39. Sharma, S.S.; Pledger, W.J. The non-canonical functions of p27Kip1 in normal and tumor biology. Cell Cycle 2016, 15, 1189–1201. [Google Scholar] [CrossRef]
  40. Tian, Y.-F.; Chen, T.-J.; Lin, C.-Y.; Chen, L.-T.; Lin, L.-C.; Hsing, C.-H.; Lee, S.-W.; Sheu, M.-J.; Lee, H.-H.; Shiue, Y.-L.; et al. SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential. Tumor Biol. 2013, 34, 1107–1117. [Google Scholar] [CrossRef]
  41. Zhong, S.; Li, Y.-G.; Ji, D.-F.; Lin, T.-B.; Lv, Z.-Q. Protocatechualdehyde induces S-phase arrest and apoptosis by stimulating the p27KIP1-Cyclin A/D1-CDK2 and mitochondrial apoptotic pathways in HT-29 cells. Molecules 2016, 21, 934. [Google Scholar] [CrossRef]
  42. Luo, J.; Zhao, H.; Chen, L.; Liu, M. Multifaceted functions of RPS27a: An unconventional ribosomal protein. J. Cell. Physiol. 2023, 238, 485–497. [Google Scholar] [CrossRef]
  43. Warner, J.R.; McIntosh, K.B. How common are extraribosomal functions of ribosomal proteins? Mol. Cell 2009, 34, 3–11. [Google Scholar] [CrossRef]
  44. Wool, I.G. Extraribosomal functions of ribosomal proteins. Trends Biochem. Sci. 1996, 21, 164–165. [Google Scholar] [CrossRef]
  45. Wang, H.; Yu, J.; Zhang, L.; Xiong, Y.; Chen, S.; Xing, H.; Tian, Z.; Tang, K.; Wei, H.; Rao, Q.; et al. RPS27a promotes proliferation, regulates cell cycle progression and inhibits apoptosis of leukemia cells. Biochem. Biophys. Res. Commun. 2014, 446, 1204–1210. [Google Scholar] [CrossRef]
  46. Sun, X.-X.; DeVine, T.; Challagundla, K.B.; Dai, M.-S. Interplay between ribosomal protein S27a and MDM2 protein in p53 activation in response to ribosomal stress. J. Biol. Chem. 2011, 286, 22730–22741. [Google Scholar] [CrossRef] [PubMed]
  47. Adams, S.; Sharp, M.; Walker, R.; Brammar, W.; Varley, J. Differential expression of translation-associated genes in benign and malignant human breast tumours. Br. J. Cancer 1992, 65, 65–71. [Google Scholar] [CrossRef] [PubMed]
  48. Wong, J.M.; Mafune, K.; Yow, H.; Rivers, E.N.; Ravikumar, T.; Steele, G.D., Jr.; Chen, L.B. Ubiquitin-ribosomal protein S27a gene overexpressed in human colorectal carcinoma is an early growth response gene. Cancer Res. 1993, 53, 1916–1920. [Google Scholar] [PubMed]
  49. Kanayama, H.; Tanaka, K.; Aki, M.; Kagawa, S.; Miyaji, H.; Satoh, M.; Okada, F.; Sato, S.; Shimbara, N.; Ichihara, A. Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res. 1991, 51, 6677–6685. [Google Scholar]
  50. Fatima, G.; Mathan, G.; Kumar, V. The HBx protein of hepatitis B virus regulates the expression, intracellular distribution and functions of ribosomal protein S27a. J. Gen. Virol. 2012, 93, 706–715. [Google Scholar] [CrossRef]
  51. Contin, R.; Arnoldi, F.; Mano, M.; Burrone, O. Rotavirus replication requires a functional proteasome for effective assembly of viroplasms. J. Virol. 2011, 85, 2781–2792. [Google Scholar] [CrossRef]
  52. Sun, Y.; Zhang, M.; Dou, J.; Wang, X.; Dai, X.; Li, X. Effects of Astragalus membranaceus (Fisch.) Bunge.on Piglets Flora Imbalance Diarrhea Based on Network Pharmacology and Molecular Docking. China Anim. Husb. Vet. Med. 2022, 49, 3200–3211. [Google Scholar]
  53. Rong, Q.; Liu, J.; Cheng, Y.; Wang, Y.; Gong, L.; Sun, F. Exploring the Molecular Mechanism of Mulberry leaf and Eucommia ulmoides Against Infectious Bursal Disease of Poultry Based on Network Pharmacology. China Anim. Husb. Vet. Med. 2024, 51, 392–406. [Google Scholar]
  54. Kim, S.; Chen, J.; Cheng, T.; Gindulyte, A.; He, J.; He, S.; Li, Q.; Shoemaker, B.A.; Thiessen, P.A.; Yu, B.; et al. PubChem in 2021: New data content and improved web interfaces. Nucleic Acids Res. 2021, 49, D1388–D1395. [Google Scholar] [CrossRef] [PubMed]
  55. Liu, X.; Ouyang, S.; Yu, B.; Liu, Y.; Huang, K.; Gong, J.; Zheng, S.; Li, Z.; Li, H.; Jiang, H. PharmMapper server: A web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res. 2010, 38, W609–W614. [Google Scholar] [CrossRef] [PubMed]
  56. Abugessaisa, I.; Kasukawa, T. Practical Guide to Life Science Databases; Springer: Berlin/Heidelberg, Germany, 2021. [Google Scholar]
  57. Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, 2020. Huntington Disease; HD. Available online: https://omim.org/ (accessed on 1 May 2024).
  58. Amberger, J.S.; Bocchini, C.A.; Scott, A.F.; Hamosh, A. OMIM.org: Leveraging knowledge across phenotype–gene relationships. Nucleic Acids Res. 2019, 47, D1038–D1043. [Google Scholar] [CrossRef]
  59. Chen, H.; Boutros, P.C. VennDiagram: A package for the generation of highly-customizable Venn and Euler diagrams in R. BMC Bioinform. 2011, 12, 35. [Google Scholar] [CrossRef]
  60. Szklarczyk, D.; Gable, A.L.; Lyon, D.; Junge, A.; Wyder, S.; Huerta-Cepas, J.; Simonovic, M.; Doncheva, N.T.; Morris, J.H.; Bork, P.; et al. STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019, 47, D607–D613. [Google Scholar] [CrossRef]
  61. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13, 2498–2504. [Google Scholar] [CrossRef]
  62. Sherman, B.T.; Hao, M.; Qiu, J.; Jiao, X.; Baseler, M.W.; Lane, H.C.; Imamichi, T.; Chang, W. DAVID: A web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022, 50, W216–W221. [Google Scholar] [CrossRef]
  63. Kanehisa, M.; Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000, 28, 27–30. [Google Scholar] [CrossRef]
  64. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009, 30, 2785–2791. [Google Scholar] [CrossRef]
  65. Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639–1662. [Google Scholar] [CrossRef]
  66. Forster, A.; van Lenthe, E.; Spadetto, E.; Visscher, L. Two-component GW calculations: Cubic scaling implementation and comparison of vertex-corrected and partially self-consistent GW variants. J. Chem. Theory Comput. 2023, 19, 5958–5976. [Google Scholar] [CrossRef]
  67. Berendsen, H.J.; van der Spoel, D.; van Drunen, R. GROMACS: A message-passing parallel molecular dynamics implementation. Comput. Phys. Commun. 1995, 91, 43–56. [Google Scholar] [CrossRef]
Ijms 26 10884 g001
Figure 1. Intersection of Chicoric acid and anti-influenza virus targets.
Figure 1. Intersection of Chicoric acid and anti-influenza virus targets.
Ijms 26 10884 g001
Ijms 26 10884 g002
Figure 2. Potential target protein interaction network of Chicoric acid.
Figure 2. Potential target protein interaction network of Chicoric acid.
Ijms 26 10884 g002
Ijms 26 10884 g003
Figure 3. Order of anti-influenza virus potential target values of Chicoric acid.
Figure 3. Order of anti-influenza virus potential target values of Chicoric acid.
Ijms 26 10884 g003
Ijms 26 10884 g004
Figure 4. Hithub network of Chicoric acid anti-influenza virus target proteins.
Figure 4. Hithub network of Chicoric acid anti-influenza virus target proteins.
Ijms 26 10884 g004
Ijms 26 10884 g005
Figure 5. GO enrichment analysis of Chicoric acid anti-influenza virus target.
Figure 5. GO enrichment analysis of Chicoric acid anti-influenza virus target.
Ijms 26 10884 g005
Ijms 26 10884 g006
Figure 6. KEGG pathway analysis of Chicoric acid anti−influenza virus target.
Figure 6. KEGG pathway analysis of Chicoric acid anti−influenza virus target.
Ijms 26 10884 g006
Ijms 26 10884 g007
Figure 7. Network model of Chicoric acid–target–pathway.
Figure 7. Network model of Chicoric acid–target–pathway.
Ijms 26 10884 g007
Ijms 26 10884 g008
Figure 8. Molecular docking result of Chicoric acid with core target proteins. The green structures represent Chicoric acid, the blue structures indicate the binding sites of different receptor proteins with Chicoric acid, and the yellow dashed lines represent hydrogen bonds.
Figure 8. Molecular docking result of Chicoric acid with core target proteins. The green structures represent Chicoric acid, the blue structures indicate the binding sites of different receptor proteins with Chicoric acid, and the yellow dashed lines represent hydrogen bonds.
Ijms 26 10884 g008
Ijms 26 10884 g009
Figure 9. RMSD analysis of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Figure 9. RMSD analysis of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Ijms 26 10884 g009
Ijms 26 10884 g010
Figure 10. Rg analysis of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Figure 10. Rg analysis of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Ijms 26 10884 g010
Ijms 26 10884 g011
Figure 11. RMSF analysis of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Figure 11. RMSF analysis of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Ijms 26 10884 g011
Ijms 26 10884 g012
Figure 12. Distance evolution between ligand and protein binding pocket of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Figure 12. Distance evolution between ligand and protein binding pocket of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Ijms 26 10884 g012
Ijms 26 10884 g013
Figure 13. Buried SASA analysis of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Figure 13. Buried SASA analysis of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Ijms 26 10884 g013
Ijms 26 10884 g014
Figure 14. Superposition of binding conformation analysis of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Figure 14. Superposition of binding conformation analysis of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Ijms 26 10884 g014
Ijms 26 10884 g015
Figure 15. Hydrogen bond population dynamics of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Figure 15. Hydrogen bond population dynamics of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Ijms 26 10884 g015
Ijms 26 10884 g016
Figure 16. Hydrogen bond frequency analysis of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Figure 16. Hydrogen bond frequency analysis of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Ijms 26 10884 g016
Ijms 26 10884 g017
Figure 17. Electrostatic and van der Waals interaction analysis of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Figure 17. Electrostatic and van der Waals interaction analysis of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Ijms 26 10884 g017
Ijms 26 10884 g018
Figure 18. Residue contribution analysis of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Figure 18. Residue contribution analysis of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Ijms 26 10884 g018
Ijms 26 10884 g019
Figure 19. Structural analysis of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Figure 19. Structural analysis of molecular dynamics simulation results of UBC, HCK, and UBA52 with Chicoric acid: (A) UBC, (B) HCK, and (C) UBA52.
Ijms 26 10884 g019
Table 1. Anti-influenza virus targets of Chicoric acid.
Table 1. Anti-influenza virus targets of Chicoric acid.
Serial NumberUniport IDGeneName
1Q9Y6I3EPN1Epsin-1
2Q29122MYO6Unconventional myosin-VI
3P52948NUP98Nuclear pore complex protein Nup98-Nup96
4P12004PCNAProliferating Cell Nuclear Antigen
5P63000RAC1Rac Family Small GTPase 1
6P02788LTFLactotransferrin
7P55735SEC13Protein SEC13 homolog
8P35997RPS27ASmall ribosomal subunit protein eS27A
9P62987UBA52Ubiquitin–ribosomal protein eL40 fusion protein
10P0CG47UBBPolyubiquitin-B
11P0CG48UBCPolyubiquitin-C
12P12318FCGR2AFc Gamma Receptor IIa
13P05979PTGS1Prostaglandin G/H synthase 1
14Q9UKF6CPSF3Cleavage And Polyadenylation Specific Factor 3
15P46527CDKN1BCyclin-Dependent Kinase Inhibitor 1B
16P78536ADAM17ADAM Metallopeptidase Domain 17
17P06681C2Complement C2
18P19878NCF2Neutrophil cytosol factor 2
19P00156MT-CYBCytochrome b
20P00491PNPPurine nucleoside phosphorylase
21P01008SERPINC1Antithrombin-III
22P08631HCKTyrosine–protein kinase HCK
23P08069IGF1RInsulin-like growth factor 1 receptor
24Q02548PAX5Paired box protein Pax-5
25Q8WYN0ATG4ACysteine protease ATG4A
26P07288KLK3Prostate-specific antigen
27Q99259GAD1Glutamate decarboxylase 1
28Q8NI35PATJInaD-like protein
29Q5T0N5FBP1Formin-binding protein 1-like
30P05198EIF2S1Eukaryotic Translation Initiation Factor 2
Subunit Alpha
31P11181DBTLipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial
Table 2. Results of docking with Chicoric acid.
Table 2. Results of docking with Chicoric acid.
GenePDB IDFree Energy of Binding/(kJ/mol)
UBC6ULH−21.57
HCK6Z3F−20.69
UBA527OWC−19.31
RPS27A6SQR−13.69
CDKN1B6P8G−12.46
Table 3. (a). Binding energy and its components for the UBC protein in a stable state. (b). Binding energy and its compositional breakdown for the HCK protein under stable conditions. (c). Binding energy and its components for the UBA52 protein under stable-state conditions.
Table 3. (a). Binding energy and its components for the UBC protein in a stable state. (b). Binding energy and its compositional breakdown for the HCK protein under stable conditions. (c). Binding energy and its components for the UBA52 protein under stable-state conditions.
ComplexΔEvdwΔEeleΔEpolΔEnonpolΔEMMPBSA−TΔSΔGbind *
(a)
Protein–Ligand−181.42 ± 2.57−72.79 ± 8.44233.84 ± 10.26−25.33 ± 0.13−45.70 ± 1.28 27.76 ± 1.34−17.94 ± 2.57
(b)
Protein–Ligand−105.75 ± 3.19−99.40 ± 5.31213.29 ± 4.44−19.17 ± 0.25−11.03 ± 5.7433.40 ± 3.5822.37 ± 4.23
(c)
Protein–Ligand−159.84 ± 2.73−18.89 ± 7.8360.75 ± 8.12−21.47 ± 0.09−139.44 ± 2.5619.92 ± 2.25−119.52 ± 1.67
Note: * ΔGbind = ΔEvdw + ΔEele + ΔEpol + ΔEnonpol − TΔS.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Guo, W.; Ye, F.; Hou, Z.; Pang, Q. Exploring the Mechanism of Action of Chicoric Acid Against Influenza Virus Infection Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation. Int. J. Mol. Sci. 2025, 26, 10884. https://doi.org/10.3390/ijms262210884

AMA Style

Guo W, Ye F, Hou Z, Pang Q. Exploring the Mechanism of Action of Chicoric Acid Against Influenza Virus Infection Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation. International Journal of Molecular Sciences. 2025; 26(22):10884. https://doi.org/10.3390/ijms262210884

Chicago/Turabian Style

Guo, Weijun, Fuhao Ye, Zengyao Hou, and Quanhai Pang. 2025. "Exploring the Mechanism of Action of Chicoric Acid Against Influenza Virus Infection Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation" International Journal of Molecular Sciences 26, no. 22: 10884. https://doi.org/10.3390/ijms262210884

APA Style

Guo, W., Ye, F., Hou, Z., & Pang, Q. (2025). Exploring the Mechanism of Action of Chicoric Acid Against Influenza Virus Infection Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation. International Journal of Molecular Sciences, 26(22), 10884. https://doi.org/10.3390/ijms262210884

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop